SCOTTSDALE, Ariz., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced the commencement of the second phase of its national expansion plan. The Company is further enhancing its Arizona cultivation and processing facility to include a commercial kitchen for infusion processes and expanded its site by an additional 10,000 square-feet.
“The expansion is a natural evolution for Item 9 Labs as we continue to develop distinctive and organic cannabis solutions for wellbeing. We foresee accelerated growth in the infused-products sector and are prepared to meet those demands,” stated Sara Gullickson, CEO of Item 9 Labs.
The executive team at Item 9 Labs has instituted a progressive approach to fill present gaps in cannabis retail inventory and advance the industry for mainstream lifestyle markets.
Gullickson represented Item 9 Labs at the 2018 XLive Conference in Las Vegas in December. She discussed cannabis laws and regulations in the live event space as part of the conference’s first Cannabis Lab spotlight program.
Headquartered in Southern Arizona, Item 9 Labs owns and operates 50 acres and is one of the largest properties in the U.S. zoned to grow and cultivate medical marijuana. This expansion is phase two in a three-phased expansion plan. This will bring the Company’s cultivation and processing facility total to 20,000 square-feet. With manufacturing expansion and the implementation of a commercial kitchen, Item 9 Labs is expected to more than double the Company’s current property revenue.
“We look forward to building strategic partnerships with out of state brands planning to enter the Arizona market, while simultaneously developing more effective products for our customer demographic,” stated Bryce Skalla, President of Item 9 Labs.
Arizona is one of the more robust medical marijuana programs in the nation, boasting over 160,000 registered patients and sales over $450 million in 2017. In quarter one of 2018, year over year, the state had an 84 percent increase in sales according to BDS Analytics.
“There is immense potential in the ingestibles sector, as well as opportunity for new and unique modalities in the cannabis space. At Item 9 Labs we are focused on developing a boutique line of premium products for the modern cannabis consumer,” explained Skalla.
Item 9 Labs is renowned for its Delta 8 THC-derived products and groundbreaking Apollo 710 vape device. Currently vape products command a 74 percent share of the Arizona concentrates market.
Over the next six months, Item 9 Labs will ramp up production to full capacity before starting the next phase of its expansion plan in November 2019.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of todays modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
Neko@provenmediaservices.com
(401)-484-4980
Investor Contact:
Jeffrey Rassas
Item 9 Labs Corp.
Jeffrey@item9labs.com
(602)463-4246